Medicare Resolution And Trauma Expansion Will Shape Future Wound Care

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

24 Apr 25

Updated

08 Nov 25

Views

228

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-71.5%

7D

-7.4%

Loading

1Y

-71.5%

7D

-7.4%

You can edit this narrative until Nov 9 3:10 AM. Then, changes will post as Updates.

Author's Valuation

US$7.3255.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 08 Nov 25

Fair value Decreased 11%

RCEL: Leadership Transition And Guidance Reset Will Drive Second Half Recovery

Analysts have lowered their price target for AVITA Medical from $8.00 to $4.00. They cite weaker-than-expected Q3 revenue, leadership changes, and the need to amend debt agreements as key factors in their revised outlook.

Shared on 17 Sep 25

Fair value Decreased 14%

Analysts have markedly reduced AVITA Medical’s price target from $9.60 to $8.26 amid lowered guidance, recurring earnings misses, and ongoing reimbursement headwinds that are pressuring demand and raising solvency concerns despite management’s optimism for a second-half recovery. Analyst Commentary Materially lowered guidance has prompted a significant reset of expectations, but management maintains confidence in a second half recovery.

Shared on 15 Aug 25

AVITA Medical’s consensus price target remains unchanged as analysts respond to materially reduced guidance and persistent reimbursement issues—with bulls viewing the lowered expectations as prudent and bears citing execution risks and near-term revenue headwinds—leaving the fair value steady at $9.60. Analyst Commentary Materially reduced guidance led to significant downward revisions in price targets.

Shared on 01 May 25

Fair value Decreased 43%

AnalystConsensusTarget Fair Value

US$7.32

55.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

32.42%

Biotech revenue growth rate

9.55%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

7.81%

Calculation

US$29.31m

Earnings '28

x

14.97x

PE Ratio '28

=

US$438.86m

Market Cap '28

US$438.86m

Market Cap '28

/

47.98m

No. shares '28

=

US$9.15

Share Price '28

US$9.15 Share Price '28

Discounted to 2025 @ 7.71% p.a.

=

US$7.32

Fair Value '25